Economic information and modeling report
Modeling overview
2 evidence topics · 2 sources
Summary
The verified economic result concerns avapritinib plus best supportive care versus best supportive care alone: the Canadian recommendation reports an ICER of $1,871,956 per QALY gained. This is comparator cost-effectiveness evidence, not a bezuclastinib budget impact estimate. No bezuclastinib-specific price or eligible budget impact model is included in the report, so comparator estimates cannot populate the product-specific model.
Canadian reimbursement recommendation: avapritinib plus BSC versus BSC alone, base-case ICER
Bezuclastinib-specific price, cost-effectiveness analysis, and budget-impact model
No evidence found.